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Prostaglandins are known to enhance the inflammatory and 
nociceptive actions of other chemical mediators of inflam- 
mation such as bradykinin. One possible mechanism for this 
sensitizing action is that prostanoids augment the release 
of neuroactive substances from sensory neurons. To initially 
test this hypothesis, we examined whether selected pros- 
taglandins could enhance the resting or bradykinin-evoked 
release of immunoreactive substance P (ISP) and/or im- 
munoreactive calcitonin gene-related peptide (ICGRP) from 
sensory neurons in culture. Bradykinin alone causes a con- 
centration-dependent increase in the release of iSP and 
iCGRP from isolated sensory neurons, and this action is abol- 
ished in the absence of extracellular calcium. Pretreating the 
neurons with PGE, (10 nM to 1 AM) potentiates the bradykinin- 
evoked release of both iSP and iCGRP by approximately two- 
to fourfold. At these concentrations, PGE, alone did not sig- 
nificantly alter peptide release. Exposing the cultures to 1 
AM PGF,,, is ineffective in altering either resting or bradykinin- 
evoked peptide release. Sensory neurons in culture contain 
cyclooxygenase-like immunoreactivity, suggesting that the 
enzyme that converts arachidonic acid to prostaglandins is 
present. In addition, pretreating cultures with W-arachidon- 
ic acid yields radiolabeled eicosanoids that cochromato- 
graph with known prostaglandin standards. Preexposing cul- 
tures to indomethacin abolishes the production of 
prostaglandins and attenuates the bradykinin-stimulated re- 
lease of iSP and ICGRP. This implies that the synthesis of 
prostaglandins contributes to the bradykinin-evoked release 
of peptides. The augmentation of bradykinin-induced re- 
lease of iSP and iCGRP by PGE, may be one mechanism to 
account for the inflammatory and hyperalgesic actions of 
this eicosanoid. 
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Prostaglandins and bradykinin are important mediators of var- 
ious components of the inflammatory response including en- 
hanced sensitivity to noxious stimuli. Exogenous administration 
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of these agents produces symptoms characteristic of inflam- 
mation such as vasodilatation and swelling (see review by Higgs 
et al., 1984). Intradermal or intraarterial administration of bra- 
dykinin also elicits nociceptive responses in animal models of 
pain and produces overt pain in man (Ferreira, 1972; Juan and 
Lembeck, 1974; Manning et al., 199 I ; see also review by Dray 
and Perkins, 1993). Administration of prostaglandins in con- 
centrations similar to those found in inflammatory exudates 
does not cause overt pain, but rather increases sensitivity to 
noxious stimuli (Willis and Cornelsen, 1973; Ferreira et al., 
1978; Juan, 1978; Taiwo and Levine, 1989). 
Various components of inflammation result from activation 
of small-diameter sensory neurons (Bayliss, 190 1; Jancso et al., 
1967; Kenins, 198 1; Besson and Chaouch, 1987; Szolcsanyi, 
1988). Thus, it is possible that the inflammatory and nociceptive 
effects of bradykinin and/or prostaglandins originate, in part, 
from an action on these neurons. Indeed, bradykinin receptors 
are found on sensory neurons (Steranka et al., 1988) and the 
intraarterial administration ofbradykinin results in an increased 
firing of small-diameter sensory fibers (Beck and Handwerker, 
1974; Juan and Lembeck, 1974; Kanaka et al., 1985; Kumazawa 
et al., 199 I ). Furthermore, in sensory neurons grown in culture, 
bradykinin causes an increase in cell firing (Baccaglini and Ho- 
gan, 1983) suggesting a direct excitatory action of this agent. 
Prostaglandins also affect sensory neurons, although the ac- 
tions are largely to sensitize the neurons to other stimuli. For 
example, Handwerker (1976) showed that prostaglandin E, 
(PGE,) or prostaglandin E, (PGE,) increased the number of 
discharges evoked by thermal stimulation in C-fibers. Similarly, 
prostanoids sensitize A-6 fibers (Pateromichelakis and Rood, 
1982) and increase the firing of group III and IV afferent fibers 
in response to mechanical stimulation (Mense, 198 1; Schaible 
and Schmidt, 1988). PGE, and PGE, also enhance the activation 
of small-diameter sensory nerve fibers elicited by endogenous 
or exogenous inflammatory agents such as potassium, bradyki- 
nin, or capsaicin (Chahl and Iggo, 1972: Baccaglini and Hogan, 
1983; Yanagisawa et al., 1986; Schaible and Schmidt, 1988; 
Grubb et al., 199 1). 
Although prostaglandins can increase the bradykinin-induced 
excitability of sensory neurons, the question remains as to 
whether these agents can enhance the bradykinin-stimulated 
release of neurotransmitters from these neurons. This question 
is important because the release of neuroactive peptides such 
as substance P (SP) or calcitonin gene-related peptide (CGRP) 
from sensory nerve terminals in peripheral tissues may initiate 
neurogenic inflammation (Foreman, 1987; Payan, 1989) where- 
as release at terminals in the dorsal spinal cord may enhance 
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pain signaling (Cuello, 1987; Oku et al., 1987; Kuraishi et al., 
1988). Thus, augmentation of peptide release by prostaglandins 
may be a mechanism to account for the inflammatory and hy- 
peralgesic actions of these agents. We therefore examined the 
effects of low concentrations of prostaglandins on the resting 
and bradykinin-evoked release of SP-like and CGRP-like im- 
munoreactive substances (iSP, iCGRP) from rat sensory neu- 
rons grown in culture. We utilized isolated sensory neurons as 
a model for studying modulation of release because it allows 
the determination of the direct effects of prostaglandins and 
bradykinin on peptide release with minimal interference from 
other neuronal input and from non-neuronal tissues. 
Our results indicate that exposing the neuronal cultures to 
nanomolar concentrations of PGEz results in a significant en- 
hancement of the bradykinin-stimulated release of both pep- 
tides. Furthermore, the release ofpeptides evoked by bradykinin 
alone is attenuated but not eliminated by pretreating cultures 
with indomethacin. These results and the observation that the 
isolated sensory neurons have the capability of synthesizing 
prostaglandins suggest that a component ofthe bradykinin stim- 
ulation involves prostaglandins. 
Preliminary findings from these studies have appeared in ab- 
stract form (Waite and Vasko, 199 1, 1992). 
Materials and Methods 
Materials. All experiments were performed using primary cultures of 
sensory neurons harvested from the dorsal root ganglia of 15-l 7-d-old 
rat embryos. Timed-pregnant Sprague-Dawley rats were obtained from 
Harlan-Sprague Dawley, Inc. (Indianapolis, IN). Prostaglandins and 
rabbit anti-cyclooxygenase antibody were purchased from Cayman 
Chemical Co. (Ann Arbor, MI), peptides from Peninsula Laboratories 
(Belmont, CA), and routine chemicals from Sigma Chemical Company 
(St. Louis, MO). Cell culture supplies were purchased from GIBCG- 
Bethesda Research Labs (Grand Island, NY) and nerve growth factor 
from Harlan Bioproducts for Science, Inc. (Indianapolis, IN). The SP 
antiserum was raised in our laboratory, whereas the CGRP antiserum 
was kindly donated by Dr. Michael Iadorola. Goat serum and goat anti- 
rabbit antibody were purchased from Jackson Immunoresearch Labo- 
ratories, Inc. (West Grove, PA), and 14C-arachidonic acid from DuPont 
New England Nuclear (Boston, MA). Eicosanoids and indomethacin 
were initially dissolved in I -methyl-2-pyrrolidinone (Aldrich Chemical 
Co., Milwaukee, WI) and then diluted to the appropriate concentrations 
with buffer. 
All procedures used in these studies were approved by the Animal 
Care and Use Committee at Indiana University School of Medicine, 
Indianapolis, IN. 
Cell culture. Dorsal root ganglia cells were harvested and grown in 
culture as previously described (Vasko et al., 1993). Briefly, pregnant 
rats (days 15-l 7 of gestation) were placed into a chamber containing 
CO, and then sacrificed by cervical dislocation after they were rendered 
unconscious. Embryos were removed from the uterus and placed in a 
dish containing calcium-free and magnesium-free Hank’s balanced salt 
solution (HBSS) of the following composition (in mM): 17 I NaCI, 6.7 
KCI, 1.6 Na,HPO,. 0.5 KH?PO,, 6 D-glucose, and 0.01% phenol red, 
pH 7.3 at 4°C. The dorsal root ganglia (DRG) were dissected from each 
embryo and placed into a dish containing HBSS at 4°C. After the DRGs 
were removed from all of the embryos, the ganglia were transferred to 
a I5 ml centrifuge tube and allowed to settle. The buffer was carefully 
aspirated, and the ganglia were resuspended in 3 ml of HBSS containing 
0.0 1% collagenase and incubated at 37°C for 40 min. The collagenase 
solution then was removed and the ganglia were washed once with 3 
ml of fresh HBSS. After the ganglia were centrifuged at 200 x g for I 
min, the supernatant was aspirated, and the ganglia were resuspended 
in 3 ml of Dulbecco’s Minimum Essential Medium (DMEM), supple- 
mented with 2 mM glutamine, 50 &ml penicillin and streptomycin, 
10% (v/v) heat-inactivated fetal bovine serum, 50 PM 5-Buoro-2’-deoxy- 
uridine, 150 PM uridine, and 100-250 @ml nerve growth factor. The 
individual cells were dissociated by mechanical agitation using a fire- 
polished Pasteur pipette until tissue fragments were no longer visible. 
The cells were counted using a hemocytometer and approximately 
125,000 cells were added to individual wells of a 24-well Falcon culture 
dish coated with 0.5 mg/ml rat-tail collagen. Additional medium was 
added to make a final volume of 0.5 ml/well. The wells were incubated 
at 37°C in a 5% CO?, 95% air atmosphere, and the medium was changed 
every 2 d. 
Peptide release protocol. After 9-l 2 d in culture, release studies were 
performed using a modification of our previously described method 
(Nicol et al., 1992). The medium was gently aspirated from the culture 
dish and the cells washed with 0.5 ml of HEPES buffer consisting of (in 
mM) 22.5 HEPES, 135 NaCI, 3.5 KCI, 1 MgCI,, 2.5 CaCI,, 3.3 glucose, 
0.1% bovine serum albumin, and 0.003% bacitracin, pH 7.4 and main- 
tained at 36-37°C. Cells were then incubated for three consecutive 10 
min periods with 0.4 ml of HEPES buffer. The initial incubation was 
with HEPES buffer in the absence or presence of PGE?, or PGF2,, to 
measure resting release (referred to in the text as basal release). This 
was followed by incubating the cells for IO min in buffer containing 
bradykinin in the absence or presence of eicosanoids or 50 mM KC1 
substituted for equimolar NaCI. The cells were subsequently exposed 
to HEPES buffer alone to reestablish basal release. Durina each incu- 
bation, the cells were maintained at 37°C in a 5% CO, environment. 
After each 10 min incubation, the buffer was removed, aliquoted, and 
assayed for iSP and iCGRP as described below. 
The effect of a drug pretreatment was compared between wells of 
neurons exposed to a test substance and bradykinin and wells of neurons 
dissociated and plated at the same time exposed to bradykinin and 
vehicle. The vehicle, 1-methyl-2-pyrrolidinone, did not alter either the 
basal or bradykinin-stimulated release of iSP or iCGRP. To determine 
the dependence of release on extracellular calcium, cells were exposed 
to HEPES buffer minus CaCI, containing 3 mM EGTA during the release 
protocol. The calculated free calcium concentration using this buffer 
was approximately 0.1 nM (Caldwell, 1970). assuming a contamination 
of 5 FM calcium in the water. 
Radioimmunoassay qf peptides. The amount of iSP and iCGRP in 
the incubation buffers was measured directly from an aliquot using 
radioimmunoassay. To assay iSP, 25 ~1 of 1:7000 dilution of 57P anti- 
SP serum (Pang and Vasko, 1986) and 25 ~1 of 1’51-(8-Tyr)-SPcontaining 
6000-8000 cpm was added to 300 ~1 of each incubation buffer. For 
iCGRP, 250 ~1 of HEPES buffer was added to a 50 ~1 aliquot of each 
unknown sample. To each sample, 25 ~1 of the 1:71,000 dilution of 
rabbit anti-CGRP antiserum (Traub et al., 1989) and 25 ~1 of ‘lSI-(OTyr)- 
CGRP,, 1, containina 3000-4000 cum were added. The samules were 
incubated at 4°C for approximately 16 hr. The unbound peptides were 
separated from those bound to antibodies by addition of 0.5 ml of 0.1 
M phosphate buffer, pH 7.4, containing 1% Norite I charcoal, 50 mM 
NaCI, and I mg/ml bovine serum albumin. This mixture was centrifuged 
at 1500 x g for 25 min at 4°C. The supernatant was decanted and the 
radioactivity measured on a gamma scintillation spectrometer. The per- 
centage of bound radioactivity in unknown samples was compared to 
standard curves prepared with each release experiment using a nonlinear 
regression analysis. For each chemical manipulation, standard curves 
were determined in the presence of the highest concentration of test 
compound to confirm that the experimental manipulation did not alter 
the standard curves. 
Chromatography qf CGRP-like immunoreactivitv. We have previ- 
ously demonstrated that the SP-like immunoreactive substance released 
from sensory neurons cochromatographs with SP standard, suggesting 
that the compound we were assaying was authentic SP (Vasko et al., 
1993). We performed a similar procedure with the CGRP-like immu- 
noreactive substance using a modification of the method of Traub et 
al. (1989). Eighteen wells of neurons were exposed to 30 mM KCI for 
IO min to release the immunoreactive CGRP-like substance. Samples 
were pooled, lyophilized, and then resuspended in 10% acetonitrile, 
0.1% trifluoroacetic acid and injected onto a 0.4 x 25 cm C-8 HPLC 
column (Axxiom, Thompson Instruments). The column was equili- 
brated in 10% acetonitrile, 0.1% trifluoroacetic acid and the injected 
sample was eluted using a lo-60% gradient of acetonitrile, 0.1% tri- 
fluoroacetic acid. The gradient increased at a rate of 1% acetonitrile/ 
min. The flow rate was 1 ml/min and fractions were collected at I min 
intervals. A parallel analysis was performed using rat CGRP,.,, stan- 
dard. As can be seen in Figure 1, the majority of the CGRP-like im- 
munoreactive substance released from the neuronal cultures cochro- 
matographs with CGRP standard, whereas a small amount of 
immunoreactive substance elutes prior to the standard. This result sug- 
gests that a large majority of the immunoreactive substance released 
from isolated sensory neurons is authentic CGRP. 
Chromatography of arachidonic acid metabolites. Approximately 
350,000 cells were placed on collagen-coated culture dishes, 30 mm in 
diameter, and the cells grown for 9-l 2 d. Four wells of cells were pre- 
treated with 28 PM indomethacin by adding the drug to the medium 
for 30 min, while four wells received vehicle. After the preincubation, 
the medium was asoirated. the cells washed with 3 ml of HEPES buffer, 
and the cultures incubated for 30 min in HEPES buffer containing 0. i 
MM arachidonic acid, 19 ELM calcium ionophore A23 187, and approxi- 
mately 200,000 cpm of 14C-arachidonic acid. We add nonlabeled ara- 
chidonic acid to the buffer to reduce the specific activity and enhance 
the formation of radiolabeled oxygenated products. This is because 
radiolabeled arachidonic acid with a high specific activity is extensively 
taken up into phospholipids, and thus little substrate is available for 
metabolism. The cells were scraped from the culture dishes in the pres- 
ence of the HEPES buffer and the solution immediately frozen. After 
thawing, the buffer was acidified to pH 3.0 and the radiolabeled ara- 
chidonic acid metabolites extracted by adding 100% ethanol to make a 
final solution of 15% ethanol (v/v). This solution was added to octa- 
decylsilica (ODS) extraction columns that were prewashed with 5 ml of 
ethanol and then 5 ml of distilled water. The columns then were washed 
consecutively with 5 ml of 15% ethanol in water, 5 ml of water, and 5 
ml of petroleum ether. The 14C prostaglandins were eluted with 5 ml 
of ethyl acetate and dried under a nitrogen stream. 
The dried extracts were resuspended in 200 ~1 of an acetonitrile: 
water : phosphate buffer solution (3 1:69:0.01, v/v/v) containing non- 
radiolabeled prostaglandin standards. Radiolabeled metabolites of ar- 
achidonic acid and prostaglandin standards were separated by reverse- 
phase HPLC using a Beckman 334 chromatographic system with a 
Unimetrics Lichrosorb RP- 18 (5 urn) column. Eicosanoids were eluted 
with a solution of 0.01 M phosphoric acid in water containing 3 1% 
acetonitrile at a flow rate of 1 ml/min. Absorbance was monitored at 
194 nm with a Beckman UV detector to determine the elution of the 
prostaglandin standards. The column effluent was collected in 0.5 ml 
fractions, and the radioactivity was quantified by liquid scintillation 
spectroscopy. The identity of radioactive peaks was established by com- 
paring retention times of these peaks and coinjected prostaglandin stan- 
dards detected by UV absorbance. 
Cyclooxygenase immunochemistry. Sensory neurons grown in culture 
for 9 d were washed in phosphate-buffered saline (PBS) consisting of 
(in mM) 20 NaCl, 2.7 KCI, 10 NaH,PO,, and 0.2% BSA, pH 7.4. Cells 
were fixed with an ethanol : methanol (1: 1 v/v) solution for 5 min at 
4°C. Cells then were washed with PBS and incubated for 20 min in PBS 
containing rabbit anti-cyclooxygenase antibody (1: 150 dilution). The 
cells were washed again with PBS and exposed to normal goat serum 
(1:20 dilution) in PBS for 20 min before incubation with Texas red goat 
anti-rabbit antibody (1: 100 dilution) for 30 min at 37°C. Cells were 
washed for 30-45 min in PBS and then viewed by phase-contrast and 
fluorescent microscopy using a confocal microscope. 
Statistical analysis. All release data are presented as the mean -t 
standard error of the mean (SEM) from wells of neurons plated on at 
least 3 different days. Paired Student’s t test was used for comparison 
of basal (resting) release and stimulated release. When comparing more 
than two groups, an overall test based on the analysis of variance was 
nerformed. If  this test indicated that a difference existed, then Fisher’s 
LSD procedure for multiple comparisons was used. The significance 
level for all tests was set at 0.05. 
Results 
Bradykinin stimulates the release of iSP and iCGRP 
Because the administration of bradykinin appears to activate 
sensory neurons directly in a number of preparations (Beck and 
Handwerker, 1974; Baccaglini and Hogan, 1983; Kanaka et al., 
1985), we examined whether this peptide could evoke the release 
of iSP and/or iCGRP from sensory neurons grown in culture. 
As can be seen in Table 1, bradykinin causes a concentration- 
dependent increase in the release of both iSP and iCGRP. A 10 
min exposure of the cultures to 10 nM bradykinin does not alter 
iSP release significantly but causes a statistically significant in- 
crease in iCGRP release. However, 100 nM produces a two- to 
threefold increase in release of both peptides, whereas 1 PM 
bradykinin results in a six- to eightfold increase. For iSP, the 
magnitude of the release evoked by I FM bradykinin is similar 
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Figure 1. HPLC chromatography of rat CGRP,_,, and of the immu- 
noreactive product released from rat sensory neurons. The ordinate 
represents the CGRP-like immunoreactivity (in fmol) that were mea- 
sured by the radioimmunoassay. The abscissa represents 1 ml fractions 
of eluate. The top chromatograph is of CGRP standard, whereas the 
bottom is the immunoreactive substance released from neurons exposed 
to 30 mM KCI. 
to that produced by exposure to 50 mM KCl, whereas for iCGRP 
the release is approximately 50% less than potassium-stimulated 
release. 
To determine if the bradykinin-induced increase in peptide 
release was dependent on extracellular calcium, release was ex- 
amined in buffer containing 3 mM EGTA and no added CaCl,. 
Under these conditions, the basal peptide release (resting re- 
lease) is not altered but the release induced by 100 nM bradykinin 
is completely abolished (Table 1). These results indicate that 
the bradykinin-stimulated release is dependent on extracellular 
calcium and suggest that release from isolated sensory neurons 
represents a physiological process similar to that observed in 
other neuronal preparations. 
Prostaglandin E2 potentiates bradykinin-stimulated release of 
iSP and iCGRP 
In behavioral and electrophysiological studies of sensory neuron 
function, prostaglandins enhance the actions ofbradykinin (Fer- 
reira, 1972; Schaible and Schmidt, 1988; Grubb et al., 1991). 
Therefore, we wished to determine whether pretreating isolated 
sensory neurons with prostaglandins would enhance the release 
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Figure 2. Prostaglandin E2 enhances the bradykinin-stimulated release 
of iSP from rat sensory neurons. The ordinates represent the amount 
of peptide released in femtomoles per well for a 10 min incubation. 
Each bar represents the mean -+ SEM of the amount of iSP released for 
the number of wells indicated. Open bars show release when cells were 
exposed to HEPES buffer in the absence of bradykinin or PGEz (basal 
release), hatched bars indicate release when cells were exposed to 1 PM 
PGE, alone, and shaded bars are release in the presence of bradykinin 
(/efl panels) or bradykinin and PGE, after a 10 min pretreatment with 
1 PM PGE, (right panels). In A, cells were treated with 10 nM bradykinin, 
whereas in B, cells were treated with 100 nM bradykinin. *, statistically 
significant differences from basal release; 1, significant differences be- 
tween release with bradykinin in the absence and presence of PGE,. 
evoked by bradykinin. As discussed above, when sensory neu- 
rons are exposed to 10 nM bradykinin for 10 min there is no 
significant increase in iSP release (Fig. 2A, left; Table 1). How- 
ever, 1 PM PGE, given for 10 min prior to and with 10 nM 
bradykinin increases iSP release approximately twofold com- 
pared to basal release and release in the presence of bradykinin 
and vehicle. PGEz enhances the release of iSP in the presence 
of bradykinin from 2 1 f  3 fmol/well/lO min to 52 + 5 fmol/ 
well/l0 min. In a similar manner, pretreating the cells with 1 
FM PGE, significantly enhances release evoked by 100 nM bra- 
dykinin from 56 f  7 to 87 + 10 fmol/well/IO min (Fig. 2B). 
This concentration of PGE,, however, does not alter peptide 
release during the 10 min interval prior to bradykinin, as in- 
dicated by the hatched bars in Figure 2. Furthermore, when cells 
are exposed to this prostanoid for up to 30 min, no significant 
change in release is observed (data not shown). 
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Figure 3. Prostaglandin Ez enhances the bradykinin-stimulated release 
of iCGRP from rat sensory neurons. The ordinates represent the amount 
of peptide released in femtomoles per well for a 10 min incubation. 
Each bar represents the mean ? SEM of the amount of iCGRP released 
for the number ofwells indicated. As in Figure 2, open bars show release 
when cells were exnosed to HEPES buffer in the absence of bradvkinin 
or PGE, (basal release), hatched bars indicate release when cells were 
exposed to 1 PM PGE, alone, and shaded bars are release in the presence 
of bradykinin (/eft panels) or bradykinin and PGE, after a 10 min pre- 
treatment with 1 PM PGE, (right panels). In A, cells were treated with 
10 nM bradykinin, whereas in B, cells were treated with 100 nM bra- 
dykinin. *, statistically significant differences from basal release; 1, sig- 
nificant differences between release with bradykinin in the absence and 
presence of PGE?. 
Similar results were observed for iCGRP release from the 
same groups of cells, Ten nanomolar bradykinin causes a small, 
but statistically significant, increase in the release of iCGRP 
when given alone. However, pretreating with 1 WM PGEz aug- 
ments the bradykinin response approximately threefold over 
vehicle-treated controls from 63 * 6 to 183 ? 10 fmol/well/lO 
min (Fig. 3A), PGE, also increases the iCGRP release induced 
by 100 nM bradykinin by approximately twofold (Fig. 3B), but 
does not alter release when administered alone (hatched bars). 
Although 1 FM PGE? potentiates the bradykinin-induced re- 
lease of both iSP and iCGRP, this concentration is higher than 
amounts found in inflammatory exudates (Trang et al., 1977; 
Higgs and Salmon, 1979; Bombardieri et al., 1981). Conse- 
quently, we examined the effects of treating sensory neurons 
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Figure 4. Prostaglandin EL enhances bradykinin-stimulated release of 
iSP and iCGRP from rat sensory neurons in a concentration-dependent 
manner. The ordinates represent the amount of peptide released in fmol/ 
well/IO min. The abscissa represents the concentration of PGE, ad- 
ministered for 20 min prior to and throughout exposure to 100 nM 
bradykinin. The points on the left represent the basal release, that is, 
release from sensory neurons prior to exposure to bradykinin. Each 
point is the mean f  SEM for 15-23 wells of neurons. The diamonds 
and dashed line represent the amount of iSP released, whereas the squares 
and solid lines represent iCGRP release. *, significant difference in the 
amount of peptide released compared to that evoked by bradykinin 
alone. 
with lower concentrations of PGEZ, and these results are sum- 
marized in Figure 4. As in previous experiments, 100 nM bra- 
dykinin alone causes a statistically significant increase in peptide 
release compared to basal values. Immunoreactive SP release 
increases from 13 f  1 to 51 & 5 fmol/well/lO min (n = 23), 
whereas iCGRP release is elevated from 45 ? 5 to 234 f  28 
fmol/well/lO min (n = 23). Incubating the cultures with 1 nM 
PGE? did not alter the bradykinin-stimulated release of either 
peptide, whereas IO nM PGEz significantly increased the release 
of iSP but not iCGRP. However, exposure to 100 nM PGEz and 
bradykinin significantly increased the release of both peptides 
approximately 40% above release induced by bradykinin alone. 
Release of iSP and iCGRP increased to 74 * 7 fmol/well/lO 
min and 302 ? 50 fmol/well/lO min, respectively. 
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Figure 5. Prostaglandin Fz,, does not alter bradykinin-stimulated re- 
lease of iSP or iCGRP from rat sensory neurons. The ordinates represent 
the amount of peptide released in femtomoles per well for a IO min 
incubation. Each bar represents the mean + SEM of the amount of iSP 
or iCGRP released for the number of wells indicated. Open bars show 
release when cells are exposed to HEPES buffer in the absence of bra- 
dykinin or PGF,,. (basal release), hatched bars indicate release when cells 
are exposed to 1 KM PGF,,, alone, and shaded bars are release in the 
presence of 100 nM bradykinin (left panels) or 100 nM bradykinin and 
PGF,<, after a IO min pretreatment with 1 FM PGF,,, (right panels). The 
top panels represent iSP release, whereas the bottom panels illustrate 
iCGRP release. *, statistically significant differences from basal release. 
Table 1. Effects of bradykinin on neuropeptide release from rat sensory neurons 
Treatment 
Peptide release (fmol/well/ IO min) 
iSubstance P iCGRP 
n Basal Stimulated Basal Stimulated 
IO nM bradykinin I4 I4 * 2 21 f  3 43 k 8 63 f 6* 
100 nM bradykinin I4 I4 -+ I 56 + 7* 33 + 3 137 f 22* 
1000 nM bradykinin 5 12 2 2 93 * 5* 38 IL 4 194 +- 17* 
100 nM bradykinin, no 
added calcium, 3 mM 
EGTA 9 12* I 9+1 33 k 6 28 3~ 5 
50 mM KCI 8 9+-l 129 + 5* 31 t2 382 + 51* 
All data are presented as mean + SEM. 
* Statistically significant difference compared to basal release using ANOVA and Fisher’s LSD comparison. 
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Figure 6. Pretreating rat sensory neu- 
rons with indomethacin reduces but 
does not abolish bradykinin-stimulated 
release of iSP and iCGRP from rat sen- 
sory neurons. The ordinates represent 
the amount of peptide released (fmol/ 
well) for a 10 min incubation. Each bar 
represents he mean f SEM of iSP (top 
panels) or iCGRP (bottom panels) re- 
leased for the number of wells indicat- 
ed. Open bars show release when cells 
are exposed to HEPES buffer in the ab- 
sence of bradykinin (basal release), 
hatched bars indicate release when cells 
are exposed to I PM PGE,, and shaded 
bars are release in the presence of 100 
nM bradykinin. From left to right, each 
set ofthree columns represents neurons 
exposed to bradykinin alone, bradyki- 
nin-stimulated release in cells pretreat- 
ed with 28 fin indomethacin, cells pre- 
treated with I PM PGE, and then 
exposed to bradykinin, and cells pre- 
treated with both indomethacin and I 
PM PGE, prior to and throughout ex- 
posure to bradykinin. *, statistically sig- 
nificant differences from basal release; 
**, significant difference between re- 
lease induced by bradykinin in the pres- 
ence and absence of PGE?; 1, significant 
differences between bradykinin-in- 
duced release in the absence and pres- 
ence of indomethacin. 
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Prostaglandin FZrr does not alter release of iSP and iCGRP 
To determine if the sensitizing effect observed with PGE, is 
selective, we examined whether prostaglandin Fz,, (PGF,,,) could 
alter resting or bradykinin-stimulated release. Incubating neu- 
ronal cultures with 1 /IM PGF,,, for 10 min prior to and through- 
out the bradykinin exposure does not alter either the basal or 
bradykinin-evoked release of either iSP or iCGRP (Fig. 5). Re- 
lease of iSP after 100 nM bradykinin is 76 f 13 fmol/well/lO 
min in the absence of 1 PM PGF,,, and 89 f 14 fmol/well/lO 
min in the presence of PGF,,. For iCGRP, bradykinin-induced 
release is 346 ? 15 fmol/well/lO min, whereas release in cells 
exposed to PGF?,, and bradykinin is 401 f 32 fmol/well/lO 
min. Prostaglandin F,,, alone does not increase peptide release 
above basal levels (Fig. 5, hatched bars). These results suggest 
that prostaglandin-induced sensitization of sensory neurons is 
selective for certain eicosanoids. 
Indomethacin attenuates the bradykinin-stimulated release of 
peptides 
In many instances, the bradykinin-induced activation ofsensory 
neurons and its pain-producing effects are attenuated by the 
cyclooxygenase inhibitor indomethacin (Levine et al., 1984; 
Geppetti et al., 199 1; Rueff and Dray, 1992; Hua and Yaksh, 
1993). This suggests that the actions of this kinin are dependent 
on the synthesis of prostaglandins. Consequently, it is possible 
c 
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that the bradykinin-evoked release of iSP and iCGRP from 
isolated sensory neurons also requires production of prosta- 
glandins by the cells in culture. To test this possibility, we re- 
peated the bradykinin release experiments in cells exposed to 
28 WM indomethacin (the concentration that inhibits prosta- 
glandin formation; see Fig. 7) for 30 min prior to and throughout 
the release protocol. As can be seen in Figure 6 (top), indo- 
methacin significantly reduces the bradykinin-stimulated re- 
lease of iSP from 48 f 3 to 34 f 3 fmol/well/lO min. In a 
similar manner, indomethacin causes a decrease in the brady- 
kinin-evoked release of iCGRP from 195 + 22 to 103 * 8 fmol/ 
well/l0 min (Fig. 6, bottom). Indomethacin, however, does not 
alter the basal release of either peptide. 
The attenuation of bradykinin-stimulated release of peptides 
by indomethacin can be overcome by treating cells with PGE2. 
The iSP release evoked by the combination of 1 PM PGEz and 
100 nM bradykinin is 80 + I1 fmol/well/lO min in the absence 
of indomethacin and 84 f 6 fmol/well/lO min in the presence 
of indomethacin (Fig. 6). This represents a two- to threefold 
increase in the bradykinin-induced release of iSP by PGE,, re- 
sults analogous to those described above (see Fig. 2). Evoked 
release of iCGRP from cultures treated with 100 nM bradykinin 
and 1 PM PGE, was 328 & 50 fmol/well/lO min and 271 + 26 
fmol/well/ 10 min in the absence and presence of indomethacin, 
respectively (Fig. 6) again representing a two- to threefold in- 
crease above release by bradykinin alone. From these studies it 
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may be inferred that a component of bradykinin-stimulated 
release is derived from the formation of endogenous prosta- 
glandins by the cells in culture. 
Neuronal cultures have the capacity to produce prostaglandins 
The above data suggest that bradykinin-induced release is par- 
tially dependent on prostaglandin production in the cultures. 
Consequently, we sought to determine if sensory neurons in 
culture have the capacity to synthesize prostanoids. We there- 
fore incubated four wells of neurons with HEPES buffer con- 
taining 14C-arachidonic acid for 30 min, and then extracted and 
separated radiolabeled eicosanoids by reverse-phase HPLC. The 
HPLC elution profile for these cells is shown in Figure 7A. There 
are several peaks of radioactive material, indicating that nu- 
merous metabolic products of arachidonic acid are formed by 
sensory neuronal cultures. A number of these peaks cochro- 
matograph with prostaglandin standards, as indicated by the 
arrows, suggesting that these compounds are prostaglandins. For 
example, a major peak is observed with a retention time of 30 
min (fraction 60) that corresponds to the retention time ofPGEz. 
In a similar manner, other peaks of radiolabeled material co- 
chromatograph with PGD, and PGF?,,. When the cells were 
pretreated for 30 min with 28 PM indomethacin prior to ex- 
posure to 14C-arachidonic acid, the peaks of radiolabeled ma- 
terial associated with the formation of the prostaglandins are 
not seen (Fig. 7B). This observation suggests that the peaks 
detected after exposure to V-arachidonic acid are prostaglan- 
dins, because indomethacin is presumably blocking prostanoid 
synthesis by inhibiting cyclooxygenase activity. 
To determine if the sensory neurons contained cyclooxygen- 
ase-like immunoreactive substance and, thus, are the source for 
the arachidonate metabolites described above, cells grown in 
culture for 9 d were fixed and then exposed to rabbit anti- 
cyclooxygenase antibody and Texas red goat anti-rabbit anti- 
body as outlined in Materials and Methods. As can be seen in 
Figure 8B, exposure to anti-cyclooxygenase antibody produced 
heavy staining of the cytoplasm of sensory neurons, indicating 
the presence of cyclooxygenase-like immunoreactive material. 
In contrast, cultures treated with normal goat serum before in- 
cubation with Texas red goat anti-rabbit antibody had little if 
any intense staining (Fig. 8.4). These micrographs support the 
idea that the sensory neurons contain cyclooxygenase, the en- 
zyme necessary for prostaglandin production. These findings, 
taken with the data from Figure 7, suggest that the sensory 
neuron., are the source of prostaglandin production in our cul- 
tures. 
Discussion 
Bradykinin stimulates release qf iSP and iCGRP 
In initial experiments, we characterized the ability of bradykinin 
to evoke peptide release from embryonic sensory neurons grown 
in culture. We chose bradykinin as an agent to stimulate peptide 
release because it is an endogenous inflammatory mediator that 
has direct excitatory actions on sensory neurons (see review by 
Dray and Perkins, 1993). When isolated sensory neurons were 
exposed to bradykinin, the release of iSP and iCGRP increased 
in a concentration-dependent manner. Release is significantly 
elevated above resting levels at concentrations of bradykinin 
that are similar to those found in inflammatory exudates (Har- 
greaves et al., 1988; Kumakura et al., 1988). Furthermore, the 
bradykinin-evoked release was dependent on extracellular cal- 
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Figure 7. HPLC profile of prostaglandins synthesized by rat sensory 
neurons. The ordinate represents the radioactivity in counts per minute. 
The abscissa represents the fractions collected in 0.5 min intervals. The 
arr0w.s indicate the retention times for a number of prostaglandins as 
determined by an HPLC assay of known standards. A represents the 
extract from four wells of cells incubated for 30 min in HEPES buffer 
containing 14C-arachidonic acid (see Materials and Methods for details), 
whereas B represents the HPLC of extract from four wells exposed to 
10 mg/ml (28 PM) indomethacin for 30 min prior to and throughout 
the incubation with W-arachidonic acid. 
cium and the maximum release was similar to that exhibited 
by high extracellular potassium. 
The effects of bradykinin on our neuronal cultures are similar 
to those observed by others using various sensory nerve prep- 
arations. For example, MacLean et al. (1990) demonstrated that 
100 nM bradykinin increases the release of SP in rat nodose 
ganglia neurons grown in culture by two- to threefold over basal 
values. Geppetti and co-workers showed that infusion of mi- 
cromolar concentrations of bradykinin into the isolated guinea 
pig heart preparation increased the release ofboth iSP and iCGRP 
(Manzini et al., 1989; Geppetti et al., 1990, 1991). This was 
abolished when preparations were .pretreated with capsaicin, 
suggesting that the peptides were released from sensory neurons. 
Micromolar concentrations of bradykinin also stimulate SP re- 
lease from isolated guinea pig lung (Saria et al., 1988) and in- 
crease the release of CGRP from rat trachea (Hua and Yaksh, 
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Figure 8. Photomicrographs demonstrating localization of cyclooxygenase-like immunoreactivity in rat sensory neurons grown in culture. Pho- 
tographs are taken from the image produced by confocal imaging of sensory neurons exposed to cyclooxygenase antiserum (B) or nonspecific : Serum 
(A) and then processed as detailed in Materials and Methods. 
1993). The fact that our results are analogous to those of others 
demonstrates that bradykinin is both a useful and reliable stim- 
ulatory agent for studying the modulation of peptide release by 
inflammatory mediators. 
Prostaglandins augment hradvkinin-evoked peptide release 
Our present findings establish that pretreatment with PGEz sen- 
sitizes the sensory neurons in culture in a manner that results 
in an augmentation of the bradykinin-induced release of both 
iSP and iCGRP. This sensitization of release is observed with 
PGE, concentrations as low as 10 nM for iSP release and 100 
nM for release of iCGRP, with the maximal effect on both pep- 
tides at 1 FM PGE,. These concentrations do not stimulate pep- 
tide release when PGEz is administered alone. Furthermore, the 
levels are similar to the concentrations of PGEz found in in- 
flammatory exudates (Trang et al., 1977; Higgs and Salmon, 
1979; Bombardieri et al., 198 1). Higher concentrations were not 
examined because we have previously shown that concentra- 
tions of 5 and 10 PM PGE, directly stimulate the release of iSP 
from rat sensory neurons in culture (Vasko et al., 1993). 
This sensitizing action of PGEz in isolated sensory neurons 
is comparable to that observed in both in vitro and in situ sensory 
nerve preparations. Indeed, PGEz augments the activation of 
sensory neurons induced by various types of noxious chemical, 
thermal, or mechanical stimulation (Handwerker, 1976; Patero- 
michelakis and Rood, 1977; Mense, 198 1; Martin et al., 1987; 
Schaible and Schmidt, 1988; Rueffand Dray, 1993). In addition, 
intradermal injection of low concentrations of E-series prosta- 
glandins does not cause overt pain, but enhances the pain-pro- 
ducing actions of bradykinin and histamine (Ferreira, 1972). 
The sensitizing action we observed appears selective because 
pretreating cells with 1 FM PGF?, did not alter bradykinin- 
stimulated release. This lack of effect of PGF,,, is consistent with 
other studies demonstrating that this eicosanoid does not have 
direct actions on sensory neurons (Taiwo and Levine, 1986; 
Yanagisawa et al., 1986; Uda et al., 1990; Nicol et al., 1992; 
Vasko et al., 1993). The parallels between our results and other 
in vivo studies indicate that isolated sensory neurons are excel- 
lent model preparations for studying the cellular mechanisms 
mediating the neurogenic actions of inflammatory agents. 
Previous work by our laboratory and by others has shown 
that micromolar concentrations of prostaglandins increase pep- 
tide release in tissue preparations such as the guinea pig heart 
and the rat spinal cord slice (France-Cereceda, 1989; Geppetti 
et al., 1991; Andreeva and Rang, 1993; Vasko et al., 1993). 
These results contrast our present work, in that we did not 
observe peptide release with physiological concentrations of 
PGE?. Rather, this prostanoid sensitizes cells to the actions of 
other excitatory agents like bradykinin. It is possible that the 
increase in peptide release observed in tissues may, in part, 
reflect an action of prostaglandins on other cells. Indeed, inter- 
pretation of results using tissue.preparations is limited because 
these preparations contain heterogeneous populations of neu- 
rons and non-neuronal cells that may be sensitive to prosta- 
glandins. Furthermore, the use of relatively high concentrations 
of prostaglandins (1 O-l 00 WM) increases the likelihood that the 
eicosanoids are having multiple actions in these complex tissue 
preparations. The use of the isolated sensory nerve preparation, 
however, minimizes these limitations and thus supports the idea 
that the prostaglandins are acting directly on sensory neurons. 
It is interesting to speculate that the prostaglandin-induced 
sensitization and resulting increase in the release of neuropep- 
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tides may be one mechanism to account for some components 
of inflammatory actions of prostaglandins. Peripheral admin- 
istration of prostaglandins, especially PGE2, causes vasodila- 
tation, plasma extravasation, and hyperalgesia (Ferreira, 1972; 
Willis and Cornelsen, 1973; Ferreira et al., 1978; Juan, 1978; 
Higgs et al., 1984; Taiwo and Levine, 1989). This prostanoid 
also augments the inflammatory actions ofbradykinin (Williams 
and Morley, 1973; Williams, 1979). Activation of small-di- 
ameter sensory neurons produces symptoms of neurogenic in- 
flammation that are similar in many ways to the actions of 
prostaglandins (Jancso et al., 1967, 1968; Kenins, 198 1; 
Szolcsanyi, 1988). Neurogenic inflammation results, in part, 
from the release of SP and CGRP from sensory nerve terminals 
because vasodilatation and plasma extravasation are attenuated 
by pretreatment with capsaicin (thus depleting peptides from 
small-diameter sensory neurons), by administering SP or CGRP 
antibodies, or by giving peptide antagonists (Jancso et al., 1967; 
Gamse et al., 1980; Helme and Andrews, 1985; Louis et al., 
1989; Lembeck et al., 1992). Consequently, prostaglandin re- 
lease at sites oftissue injury could sensitize sensory neurons and 
thus increase the release ofSP and CGRP. The increase in release 
of SP and CGRP from central terminals of sensory neurons 
would, presumably, augment the signaling of pain, whereas the 
increase in release from the peripheral endings would exacerbate 
the inflammatory response. 
Production of prostaglandins by sensory neurons 
A number of studies in whole animals or tissue preparations 
have shown that the excitatory actions of bradykinin in sensory 
neurons are attenuated by inhibitors of prostaglandin synthesis 
(Levine et al., 1984; Geppetti et al., 199 1; Rue11 and Dray, 1992; 
Hua and Yaksh, 1993). Furthermore, bradykinin increases the 
liberation of arachidonic acid with the formation and release of 
prostaglandins (McGiff et al., 1972; Lembeck et al., 1976; Gam- 
mon et al., 1989). Consequently, a component of the overall 
excitatory actions of bradykinin may be modulated by the action 
of endogenously produced prostaglandins. The question re- 
mains, however, as to which cells produce prostaglandins. In 
tissues, numerous types of cells exist that are capable of syn- 
thesizing eicosanoids. Our results clearly demonstrate that one 
source of prostaglandins are the sensory neurons themselves. 
This conclusion is supported by our observations that exposing 
our cultures to arachidonic acid resulted in the production of 
metabolic products that cochromatograph with known prosta- 
glandin standards. These peaks were not observed when cells 
were pretreated with indomethacin, confirming that they are, 
in fact, cyclooxygenase products of arachidonic acid metabo- 
lism. In addition, we demonstrated that a cyclooxygenase-like 
immunoreactive substance is localized in the cytoplasm of the 
sensory neurons. Thus, the sensory neurons are one source of 
the arachidonic acid metabolites. 
Because our cultures consist of all types of dorsal root ganglia 
cells, we cannot determine whether prostaglandins are produced 
in the same sensory neurons that synthesize and release the 
neuropeptides. However, pretreating our neuronal cultures with 
indomethacin attenuates the bradykinin-stimulated release of 
both iSP and iCGRP. This suggests that bradykinin enhances 
the production of prostaglandins and that this is contributing 
to the stimulatory effects of bradykinin on peptide release. It is 
therefore possible that activation of sensory neurons not only 
can increase the release of neuropeptides, but that these cells 
can autoregulate their sensitivity by producing prostaglandins. 
Further studies are needed to support or refute this possibility. 
Sensory neurons in culture and the actions qf inflammatory 
mediators 
It is important to point out that the use of sensory neurons 
grown in culture provides an important cellular model for study- 
ing the actions of inflammatory and pain mediators on sensory 
systems. This was first suggested by Baccaglini and Hogan (1983), 
who demonstrated that cultured sensory neurons represent “dif- 
ferentiated pain sensory neurons.” They showed that cultured 
neurons derived from dorsal root ganglia or trigeminal ganglia 
were excited by capsaicin and bradykinin, that the potassium 
depolarization was sensitized by prostaglandins, and that the 
cells contained SP. Our present work further illustrates the va- 
lidity of isolated sensory neurons as a cellular model for the 
investigation of neuronal sensitization. Indeed, the cells in cul- 
ture release both iSP and iCGRP in response to bradykinin or 
high extracellular potassium, agents that depolarize sensory neu- 
rons. These neurons also are sensitized by certain prostaglan- 
dins, which results in an increase in bradykinin-stimulated re- 
lease of peptides. In addition, the recent work of Nicol and Cui 
using embryonic rat sensory neurons in culture has shown that 
PGE, also sensitizes these neurons to the bradykinin-elicited 
firing of action potentials (Nicol and Cui, 1992). These sensi- 
tizing actions of PGEz are analogous to effects of this prostanoid 
in other sensory nerve preparations. Consequently, utilization 
of sensory neurons grown in culture provides a model prepa- 
ration to study directly the cellular mechanisms regulating neu- 
ropeptide release and its modulation by eicosanoids with min- 
imal contaminations by other cell types. 
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